throbber

`
`
` HIGHLIGHTS OF PRESCRIBING INFORMATION
` These highlights do not include all the information needed to use
`
`
`
` AFINITOR/AFINITOR DISPERZ safely and effectively. See full
`
` prescribing information for AFINITOR/AFINITOR DISPERZ.
`
`
` AFINITOR® (everolimus) tablets, for oral use
`
`
`
`
`AFINITOR DISPERZ® (everolimus tablets for oral suspension)
`
`
`
`Initial U.S. Approval: 2009
`
`----------------------------RECENT MAJOR CHANGES-------------------------­
`
`2/2020
`Warnings and Precautions, Risk of Impaired Wound Healing (5.7)
`
`
`
`
`
`Warnings and Precautions, Radiation Sensitization and Radiation Recall
`
`
`
`
`4/2021
`(5.12)
`
`
`----------------------------INDICATIONS AND USAGE--------------------------­
`
`AFINITOR is a kinase inhibitor indicated for the treatment of:
`
`
`
`• Postmenopausal women with advanced hormone receptor-positive, HER2­
`
`
`
`negative breast cancer in combination with exemestane after failure of
`
`
`
`treatment with letrozole or anastrozole. (1.1)
`
`
`• Adults with progressive neuroendocrine tumors of pancreatic origin
`
`
`
`
`
`(PNET) and adults with progressive, well-differentiated, non-functional
`
`
`
`
`neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that
`
`
`
`are unresectable, locally advanced or metastatic.
`
`Limitations of Use: AFINITOR is not indicated for the treatment of
`
`
`
`
`
`
`patients with functional carcinoid tumors. (1.2)
`
`
`
`
`
`
`• Adults with advanced renal cell carcinoma (RCC) after failure of treatment
`
`with sunitinib or sorafenib. (1.3)
`
`
`
`
`
`• Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC),
`
`
`
`not requiring immediate surgery. (1.4)
`
`
`AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the
`
`
`
`
`
`treatment of adult and pediatric patients aged 1 year and older with TSC who
`
`
`
`have subependymal giant cell astrocytoma (SEGA) that requires therapeutic
`
`
`intervention but cannot be curatively resected. (1.5)
`
`
`
`AFINITOR DISPERZ is a kinase inhibitor indicated for the adjunctive
`
`
`
`
`treatment of adult and pediatric patients aged 2 years and older with TSC-
`
`
`
`associated partial-onset seizures. (1.6)
`------------------------DOSAGE AND ADMINISTRATION--------------------­
`
`
`Do not combine AFINITOR and AFINITOR DISPERZ to achieve the total
`
`
`daily dose. (2.1)
`
`
`
`
`
`Modify the dose for patients with hepatic impairment or for patients taking
`
`
`
`
`
`drugs that inhibit or induce P-glycoprotein (P-gp) and CYP3A4. (2.1)
`
`
`Breast Cancer:
`
`
`
`
`
`• 10 mg orally once daily. (2.2)
`
`NET:
`
`
`
`• 10 mg orally once daily. (2.3)
`
`RCC:
`
`
`
`• 10 mg orally once daily. (2.4)
`
`
`
`TSC-Associated Renal Angiomyolipoma:
`
`
`
`
`• 10 mg orally once daily. (2.5)
`
`
`TSC-Associated SEGA:
`
`• 4.5 mg/m2 orally once daily; adjust dose to attain trough concentrations of
`
`
`
`
`
`
`5-15 ng/mL. (2.6, 2.8)
`
`
`TSC-Associated Partial-Onset Seizures:
`
`• 5 mg/m2 orally once daily; adjust dose to attain trough concentrations of 5­
`
`
`
`
`
`
`
`
`15 ng/mL. (2.7, 2.8)
`
`----------------------DOSAGE FORMS AND STRENGTHS--------------------­
`• AFINITOR: 2.5 mg, 5 mg, 7.5 mg, and 10 mg tablets (3)
`
`
`
`
`
`• AFINITOR DISPERZ: 2 mg, 3 mg, and 5 mg tablets (3)
`
`
`
`
`-------------------------------CONTRAINDICATIONS-----------------------------­
`Clinically significant hypersensitivity to everolimus or to other rapamycin
`
`
`
`
`derivatives. (4)
`
`
`---------------------------WARNINGS AND PRECAUTIONS-------------------­
`
`• Non-Infectious Pneumonitis: Monitor for clinical symptoms or radiological
`
`
`
`
`
`changes. Withhold or permanently discontinue based on severity. (2.9, 5.1)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 4780931
`
`• Infections: Monitor for signs and symptoms of infection. Withhold or
`
`
`
`
`
`permanently discontinue based on severity. (2.9, 5.2)
`
`
`
`
`• Severe Hypersensitivity Reactions: Permanently discontinue for clinically
`
`
`
`
`significant hypersensitivity. (5.3)
`
`
`• Angioedema: Patients taking concomitant angiotensin-converting-enzyme
`
`
`
`
`
`(ACE) inhibitors may be at increased risk for angioedema. Permanently
`
`
`
`
`
`
`discontinue for angioedema. (5.4, 7.2)
`
`
`• Stomatitis: Initiate dexamethasone alcohol-free mouthwash when starting
`
`
`
`
`
`
`treatment. (5.5, 6.1)
`
`
`• Renal Failure: Monitor renal function prior to treatment and periodically
`
`
`
`
`
`
`thereafter. (5.6)
`
`• Risk of Impaired Wound Healing: Withhold for at least 1 week prior to
`
`
`
`
`
`
`
`elective surgery. Do not administer for at least 2 weeks following major
`
`
`
`
`surgery and until adequate wound healing. The safety of resumption of
`
`
`
`
`treatment after resolution of wound healing complications has not been
`
`
`
`established. (5.7)
`
`• Geriatric Patients: Monitor and adjust dose for adverse reactions. (5.8)
`
`
`• Metabolic Disorders: Monitor serum glucose and lipids prior to treatment
`
`
`
`
`
`
`
`
`and periodically thereafter. Withhold or permanently discontinue based on
`
`
`
`severity. (2.9, 5.9)
`
`
`• Myelosuppression: Monitor hematologic parameters prior to treatment and
`
`
`
`
`periodically thereafter. Withhold or permanently discontinue based on
`
`
`severity. (2.9, 5.10)
`
`
`• Risk of Infection or Reduced Immune Response with Vaccination: Avoid
`
`
`
`
`
`
`
`live vaccines and close contact with those who have received live vaccines.
`
`
`
`
`Complete recommended childhood vaccinations prior to starting treatment.
`
`
`(5.11)
`
`• Radiation Sensitization and Radiation Recall: Severe radiation reactions
`
`
`
`may occur. (5.12, 6.2)
`
`
`
`• Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of
`
`
`
`
`
`reproductive potential of the potential risk to a fetus and to use effective
`
`
`
`
`
`
`
`contraception. (5.13, 8.1, 8.3)
`
`------------------------------ADVERSE REACTIONS------------------------------­
`• Breast cancer, NET, RCC: Most common adverse reactions (incidence
`
`
`
`
`
`≥ 30%) include stomatitis, infections, rash, fatigue, diarrhea, edema,
`
`
`
`
`abdominal pain, nausea, fever, asthenia, cough, headache, and decreased
`
`
`
`appetite. (6.1)
`
`• TSC-Associated Renal Angiomyolipoma: Most common adverse reaction
`
`
`
`
`
`(incidence ≥ 30%) is stomatitis. (6.1)
`
`
`• TSC-Associated SEGA: Most common adverse reactions (incidence ≥
`
`
`
`
`
`30%) are stomatitis and respiratory tract infection. (6.1)
`
`• TSC-Associated Partial-Onset Seizures: Most common adverse reaction
`
`
`
`
`(incidence ≥ 30%) is stomatitis. (6.1)
`
`
`To report SUSPECTED ADVERSE REACTIONS, contact Novartis
`
`Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA­
`
`
`1088 or www.fda.gov/medwatch.
`
`
`------------------------------DRUG INTERACTIONS------------------------------­
`• P-gp and strong CYP3A4 inhibitors: Avoid concomitant use. (2.11, 7.1)
`
`
`
`
`
`• P-gp and moderate CYP3A4 inhibitors: Reduce the dose as recommended.
`
`
`
`(2.11, 7.1)
`
`
`• P-gp and strong CYP3A4 inducers: Increase the dose as recommended.
`
`
`
`
`
`(2.12, 7.1)
`
`
`-----------------------USE IN SPECIFIC POPULATIONS-----------------------­
`• For breast cancer, NET, RCC, or TSC-associated renal angiomyolipoma
`
`
`
`patients with hepatic impairment, reduce the dose. (2.10, 8.6)
`
`
`• For patients with TSC-associated SEGA or TSC-associated partial-onset
`
`
`
`
`
`
`seizures and severe hepatic impairment, reduce the starting dose and adjust
`
`
`
`
`
`dose to attain target trough concentrations. (2.8, 2.10, 8.6)
`
`
`
`
`See 17 for PATIENT COUNSELING INFORMATION and
`
`
`FDA-approved patient labeling.
`
`
`
`
`
`
`
`
`
`
`Revised: 4/2021
`
`
`
`

`

`
`
`
`2
`
`
`
` FULL PRESCRIBING INFORMATION: CONTENTS*
`
`
`1
`INDICATIONS AND USAGE
`
`
`1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer
`
`
`
`1.2 Neuroendocrine Tumors (NET)
`
`
`
`1.3 Renal Cell Carcinoma (RCC)
`
`
`
`1.4
`Tuberous Sclerosis Complex (TSC)-Associated Renal
`
`
`
`
`Angiomyolipoma
`
`
`1.5
`Tuberous Sclerosis Complex (TSC)-Associated Subependymal
`
`
`
`
`Giant Cell Astrocytoma (SEGA)
`
`
`1.6
`Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset
`
`
`
`
`Seizures
`
`
`DOSAGE AND ADMINISTRATION
`
`
`Important Dosage Information
`
`2.1
`
`2.2 Recommended Dosage for Hormone Receptor-Positive, HER2­
`
`
`Negative Breast Cancer
`
`
`
`2.3 Recommended Dosage for Neuroendocrine Tumors (NET)
`
`
`
`2.4 Recommended Dosage for Renal Cell Carcinoma (RCC)
`
`
`
`
`2.5 Recommended Dosage for Tuberous Sclerosis Complex (TSC)­
`
`
`
`Associated Renal Angiomyolipoma
`
`
`2.6 Recommended Dosage for Tuberous Sclerosis Complex (TSC)­
`
`
`
`Associated Subependymal Giant Cell Astrocytoma (SEGA)
`
`
`
`
`2.7 Recommended Dosage for Tuberous Sclerosis Complex (TSC)­
`
`
`
`Associated Partial-Onset Seizures
`
`
`
`
`
`
`2.8
`Therapeutic Drug Monitoring (TDM) and Dose Titration for
`
`
`
`Tuberous Sclerosis Complex (TSC)-Associated Subependymal
`
`
`Giant Cell Astrocytoma (SEGA) and TSC-Associated Partial-
`
`
`Onset Seizures
`
`
`
`
`
`2.9 Dosage Modifications for Adverse Reactions
`
`
`
`2.10 Dosage Modifications for Hepatic Impairment
`
`
`
`2.11 Dosage Modifications for P-gp and CYP3A4 Inhibitors
`
`
`
`
`2.12 Dosage Modifications for P-gp and CYP3A4 Inducers
`
`
`
`
`2.13 Administration and Preparation
`
`
`
`DOSAGE FORMS AND STRENGTHS
`3
`
`
`CONTRAINDICATIONS
`4
`
`
`5 WARNINGS AND PRECAUTIONS
`
`
`5.1 Non-infectious Pneumonitis
`
`
`
`5.2
`Infections
`
`
`
`5.3
`Severe Hypersensitivity Reactions
`
`
`5.4 Angioedema with Concomitant Use of Angiotensin-Converting
`
`
`
`
`
`Enzyme (ACE) Inhibitors
`
`
`
`5.5
`Stomatitis
`
`
`
`5.6 Renal Failure
`
`
`
`5.7 Risk of Impaired Wound Healing
`
`
`
`
`6
`
`
`7
`
`
`8
`
`
`
`5.8 Geriatric Patients
`
`
`
`5.9 Metabolic Disorders
`
`
`
`5.10 Myelosuppression
`
`
`
`5.11 Risk of Infection or Reduced Immune Response with Vaccination
`
`
`
`
`
`5.12 Radiation Sensitization and Radiation Recall
`
`
`
`
`5.13 Embryo-Fetal Toxicity
`
`
`ADVERSE REACTIONS
`
`
`6.1 Clinical Trials Experience
`
`
`
`
`Postmarketing Experience
`
`6.2
`
`DRUG INTERACTIONS
`
`
`7.1
`Effect of Other Drugs on AFINITOR/AFINITOR DISPERZ
`
`
`
`
`Effects of Combination Use of Angiotensin Converting Enzyme
`
`7.2
`
`
`
`
`(ACE) Inhibitors
`
`
`USE IN SPECIFIC POPULATIONS
`
`
`8.1
`Pregnancy
`
`
`
`8.2
`Lactation
`
`
`
`8.3
`Females and Males of Reproductive Potential
`
`
`
`
`
`8.4
`Pediatric Use
`
`
`
`8.5 Geriatric Use
`
`
`
`8.6 Hepatic Impairment
`
`
`
`11 DESCRIPTION
`
`
`12 CLINICAL PHARMACOLOGY
`
`
`12.1 Mechanism of Action
`
`
`
`
`12.2 Pharmacodynamics
`
`
`
`12.3 Pharmacokinetics
`
`
`
`13 NONCLINICAL TOXICOLOGY
`
`
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`
`
`
`13.2 Animal Toxicology and/or Pharmacology
`
`
`
`
`14 CLINICAL STUDIES
`
`
`14.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer
`
`
`
`14.2 Neuroendocrine Tumors (NET)
`
`
`
`14.3 Renal Cell Carcinoma (RCC)
`
`
`
`14.4 Tuberous Sclerosis Complex (TSC)-Associated Renal
`
`
`
`
`
`Angiomyolipoma
`
`
`14.5 Tuberous Sclerosis Complex (TSC)-Associated Subependymal
`
`
`
`
`Giant Cell Astrocytoma (SEGA)
`
`
`14.6 Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset
`
`
`
`
`Seizures
`
`
`
`15 REFERENCES
`
`
`16 HOW SUPPLIED/STORAGE AND HANDLING
`
`
`17 PATIENT COUNSELING INFORMATION
`*Sections or subsections omitted from the full prescribing information are
`
`
`
`
`
`not listed
`
`
`
`
`
`Reference ID: 4780931
`
`

`

`
`
`
` FULL PRESCRIBING INFORMATION
`
`
` 1
` INDICATIONS AND USAGE
` 1.1
` Hormone Receptor-Positive, HER2-Negative Breast Cancer
`
`
`
`AFINITOR® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2­
`
`
`
`
`
`
`negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole.
`
`
`Neuroendocrine Tumors (NET)
`1.2
`
`
`
`
`
`AFINITOR is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin
`
`
`
`(PNET) with unresectable, locally advanced or metastatic disease.
`
`
`
`
`
`AFINITOR is indicated for the treatment of adult patients with progressive, well-differentiated, non-functional NET of
`
`
`
`
`
`gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease.
`
`
`
`Limitations of Use: AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors [see
`
`Clinical Studies (14.2)].
`
`
`
`Renal Cell Carcinoma (RCC)
`1.3
`
`
`
`
`
`
`AFINITOR is indicated for the treatment of adult patients with advanced RCC after failure of treatment with sunitinib or
`
`sorafenib.
`
`
`
`
`Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma
`1.4
`
`
`
`
`
`
`AFINITOR is indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate
`
`surgery.
`
`
`
`
`
`
`Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA)
`1.5
`AFINITOR and AFINITOR DISPERZ® are indicated in adult and pediatric patients aged 1 year and older with TSC for
`
`
`
`
`
`
`the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected.
`
`1.6
`Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset Seizures
`
`
`
`
`
`AFINITOR DISPERZ is indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with
`
`
`
`
`
`TSC-associated partial-onset seizures.
`
`
`
`DOSAGE AND ADMINISTRATION
`2
`
`
`2.1
`Important Dosage Information
`
`
`• AFINITOR and AFINITOR DISPERZ are two different dosage forms. Select the recommended dosage form based on
`
`
`
`
`
`
`the indication [see Indications and Usage (1)]. Do not combine AFINITOR and AFINITOR DISPERZ to achieve the
`
`
`
`
`total dose.
`
`• Modify the dosage for patients with hepatic impairment or for patients taking drugs that inhibit or induce P­
`
`
`
`
`
`glycoprotein (P-gp) and CYP3A4 [see Dosage and Administration (2.10, 2.11, 2.12)].
`
`
`Recommended Dosage for Hormone Receptor-Positive, HER2-Negative Breast Cancer
`2.2
`
`
`
`
`The recommended dosage of AFINITOR is 10 mg orally once daily until disease progression or unacceptable toxicity.
`
`
`
`
`
`
`
`Recommended Dosage for Neuroendocrine Tumors (NET)
`2.3
`
`
`
`The recommended dosage of AFINITOR is 10 mg orally once daily until disease progression or unacceptable toxicity.
`
`
`Recommended Dosage for Renal Cell Carcinoma (RCC)
`2.4
`
`
`
`The recommended dosage of AFINITOR is 10 mg orally once daily until disease progression or unacceptable toxicity.
`
`
`
`Recommended Dosage for Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma
`2.5
`
`
`
`
`
`
`The recommended dosage of AFINITOR is 10 mg orally once daily until disease progression or unacceptable toxicity.
`
`
`
`
`Reference ID: 4780931
`
`

`

`
`
`
`
` 2.6
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Recommended Dosage for Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell
`
` Astrocytoma (SEGA)
`
` The recommended starting dosage of AFINITOR/AFINITOR DISPERZ is 4.5 mg/m2 orally once daily until disease
`
` progression or unacceptable toxicity [see Dosage and Administration (2.8)].
`
`
`
`
`
`
` Recommended Dosage for Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset Seizures
` 2.7
` The recommended starting dosage of AFINITOR DISPERZ is 5 mg/m2 orally once daily until disease progression or
`
`
`
`
`
`
`
`
`
` unacceptable toxicity [see Dosage and Administration (2.8)].
`
`
` Therapeutic Drug Monitoring (TDM) and Dose Titration for Tuberous Sclerosis Complex (TSC)­
`
`
`
`
` 2.8
`
`
`
`
`
` Associated Subependymal Giant Cell Astrocytoma (SEGA) and TSC-Associated Partial-Onset Seizures
` • Monitor everolimus whole blood trough concentrations at time points recommended in Table 1.
`
`
`
`
`
`
`
` • Titrate the dose to attain trough concentrations of 5 ng/mL to 15 ng/mL.
`
`
`
`
`
` • Adjust the dose using the following equation:
`
`
`
`
` New dose* = current dose x (target concentration divided by current concentration)
`
` *The maximum dose increment at any titration must not exceed 5 mg. Multiple dose titrations may be required to
`
`
` attain the target trough concentration.
`
`
` • When possible, use the same assay and laboratory for TDM throughout treatment.
`
`
`
`Table 1: Recommended Timing of Therapeutic Drug Monitoring
`
`
`Event
`
`
` When to Assess Trough
`
`
`
`Concentrations After Event
`
` 1 to 2 weeks
`
`
` 1 to 2 weeks
`
`
` 1 to 2 weeks
`
`
` 2 weeks
`
`
` 2 weeks
`
`
` 2 weeks
`
`
` Every 3 to 6 months
`
` Every 6 to 12 months
`
`
`
`
`Initiation of AFINITOR/AFINITOR DISPERZ
`
`
`
` Modification of AFINITOR/AFINITOR DISPERZ dose
` Switch between AFINITOR and AFINITOR DISPERZ
`
`
`
`
` Initiation or discontinuation of P-gp and moderate CYP3A4 inhibitor
` Initiation or discontinuation of P-gp and strong CYP3A4 inducer
`
`
`
` Change in hepatic function
` Stable dose with changing body surface area (BSA)
`
` Stable dose with stable BSA
`
` Abbreviation: P-gp, P-glycoprotein.
`
` Dosage Modifications for Adverse Reactions
`
`
` 2.9
` Table 2 summarizes recommendations for dosage modifications of AFINITOR/AFINITOR DISPERZ for the
`
`
` management of adverse reactions.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 4780931
`
`

`

` Table 2: Recommended Dosage Modifications for AFINITOR/AFINITOR DISPERZ for Adverse Reactions
`
`
`
`
`
`
` Adverse Reaction
` Severity
` Dosage Modification
`
`
`
`
`
`Grade 2
`Withhold until improvement to Grade 0 or 1. Resume at 50% of previous
`Non-infectious
`
`
`
`
`pneumonitis
`dose; change to every other day dosing if the reduced dose is lower than
`
`
`the lowest available strength.
`
`[see Warnings and
`
`
`
`
`Permanently discontinue if toxicity does not resolve or improve to
`
`Precautions (5.1)]
`
` Grade 1 within 4 weeks.
`
` Withhold until improvement to Grade 0 or 1. Resume at 50% of previous
`
`
`
`
` dose; change to every other day dosing if the reduced dose is lower than
` the lowest available strength.
`
` If toxicity recurs at Grade 3, permanently discontinue.
`
` Permanently discontinue.
`
`
` Withhold until improvement to Grade 0 or 1. Resume at same dose.
` If recurs at Grade 2, withhold until improvement to Grade 0 or 1. Resume
`
` at 50% of previous dose; change to every other day dosing if the reduced
`
`
`
` dose is lower than the lowest available strength.
`
`
`
`
`
`Withhold until improvement to Grade 0 or 1. Resume at 50% of previous
`
`
`
`dose; change to every other day dosing if the reduced dose is lower than
`
`the lowest available strength.
`
` Permanently discontinue.
`
` Withhold until improvement to Grade 0, 1, or 2. Resume at 50% of
` previous dose; change to every other day dosing if the reduced dose is
`
`
`
` lower than the lowest available strength.
`
`
`Permanently discontinue.
`
`
`
`
`
`
`
` Stomatitis
`
`[see Warnings and
`
`Precautions (5.5)]
`
`
`
`
` Metabolic events
`
`(e.g., hyperglycemia,
`
` dyslipidemia)
`[see Warnings and
`
`
`Precautions (5.9)]
`Other non-hematologic
`toxicities
`
`
`
`
`
` Grade 3
`
`
`
` Grade 4
`
` Grade 2
`
`
`
`Grade 3
`
`
`
` Grade 4
`
` Grade 3
`
`Grade 4
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Grade 2
`
`
`
`Grade 3
`
`
` Grade 4
` Grade 2
`
`
`Grade 3
`OR
`
`
`Grade 4
`
` Grade 3
`
`Grade 4
`
`
`
`Grade 3
`
`
`If toxicity becomes intolerable, withhold until improvement to Grade 0 or
`
`
`1. Resume at same dose.
`
`If toxicity recurs at Grade 2, withhold until improvement to Grade 0 or 1.
`
`
`Resume at 50% of previous dose; change to every other day dosing if the
`
`
`
`reduced dose is lower than the lowest available strength.
`
`
`
`
`
`Withhold until improvement to Grade 0 or 1. Consider resuming at 50%
`
`
`of previous dose; change to every other day dosing if the reduced dose is
`
`
`lower than the lowest available strength.
`
`If recurs at Grade 3, permanently discontinue.
`
` Permanently discontinue.
` Withhold until improvement to Grade 0 or 1. Resume at same dose.
`
`
`
`
`
`Withhold until improvement to Grade 0 or 1. Resume at 50% of previous
`
`
`
`dose; change to every other day dosing if the reduced dose is lower than
`
`the lowest available strength.
`
` Withhold until improvement to Grade 0, 1, or 2. Resume at same dose.
`
`
`Withhold until improvement to Grade 0, 1, or 2. Resume at 50% of
`
`
`
`
`
`previous dose; change to every other day dosing if the reduced dose is
`
`
`lower than the lowest available strength.
`
`
`
`
`
`Withhold until improvement to Grade 0, 1, or 2, and no fever. Resume at
`
`
`50% of previous dose; change to every other day dosing if the reduced
`
`
`
`dose is lower than the lowest available strength.
`
`
`
`
`
`
`
` Thrombocytopenia
` [see Warnings and
`
` Precautions (5.10)]
`
`
` Neutropenia
`
` [see Warnings and
`
` Precautions (5.10)]
`
`
`
`Febrile neutropenia
`
`[see Warnings and
`
`Precautions (5.10)]
`
`Reference ID: 4780931
`
`

`

`
`
`
`
`
`
` Dosage Modification
`
`
` Severity
` Adverse Reaction
` Permanently discontinue.
`
` Grade 4
`
`2.10 Dosage Modifications for Hepatic Impairment
`
`
`
`
`The recommended dosages of AFINITOR/AFINITOR DISPERZ for patients with hepatic impairment are described in
`
`
`
`
`
`
`Table 3 [see Use in Specific Populations (8.6)]:
`
`
`
`Table 3: Recommended Dosage Modifications for Patients with Hepatic Impairment
`
`
`
`
`
` Dose Modification for AFINITOR/AFINITOR DISPERZ
`
` Indication
`
`
`
`
`
`
` Breast Cancer, NET, RCC, and
`
` TSC-Associated Renal
`
`Angiomyolipoma
`
`TSC-Associated SEGA and TSC-
` Associated Partial-Onset Seizures
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Dose Modification for AFINITOR/AFINITOR DISPERZ
`
`
`
`
`
`
`
`
`
`
`
` • Mild hepatic impairment (Child-Pugh class A) – 7.5 mg orally once daily;
`
`
`
`
`
`
`
` decrease the dose to 5 mg orally once daily if a dose of 7.5 mg once daily is
`not tolerated.
`
`• Moderate hepatic impairment (Child-Pugh class B) – 5 mg orally once daily;
`
`
`
`decrease the dose to 2.5 mg orally once daily if a dose of 5 mg once daily is
`
`
`
`
`not tolerated.
`
`
`• Severe hepatic impairment (Child-Pugh class C) – 2.5 mg orally once daily if
`
`
`the desired benefit outweighs the risk; do not exceed a dose of 2.5 mg once
`
`
`
` daily.
` • Severe hepatic impairment (Child-Pugh class C) – 2.5 mg/m2 orally once
`
`
` daily.
`
`
`
`• Adjust dose based on everolimus trough concentrations as recommended [see
` Dosage and Administration (2.8)].
`
` Abbreviations: NET, Neuroendocrine Tumors; RCC, Renal Cell Carcinoma; SEGA, Subependymal Giant Cell
`
`
` Astrocytoma; TSC, Tuberous Sclerosis Complex.
`
`
`
` 2.11 Dosage Modifications for P-gp and CYP3A4 Inhibitors
`
`
`
` • Avoid the concomitant use of P-gp and strong CYP3A4 inhibitors [see Drug Interactions (7.1)].
`
`
`
`
` • Avoid ingesting grapefruit and grapefruit juice.
`
`
`
`
`
` • Reduce the dose for patients taking AFINITOR/AFINITOR DISPERZ with a P-gp and moderate CYP3A4 inhibitor
`
`
`
` as recommended in Table 4 [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].
`
`
`
` Table 4: Recommended Dosage Modifications for Concurrent Use of AFINITOR/AFINITOR DISPERZ with a P­
`
`
`
` gp and Moderate CYP3A4 Inhibitor
`
`
`
` Indication
`
`
`
` Breast Cancer, NET, RCC, and TSC-
` Associated Renal Angiomyolipoma
`
`
`
`TSC-Associated SEGA and TSC-
` Associated Partial-Onset Seizures
`
`
`
`
`
`
` • Reduce dose to 2.5 mg once daily.
`
`
`
`
`
`
`
`• May increase dose to 5 mg once daily if tolerated.
`
` • Resume dose administered prior to inhibitor initiation, once the inhibitor is
`
`
` discontinued for 3 days.
` • Reduce the daily dose by 50%.
`
`
`
`
`
`• Change to every other day dosing if the reduced dose is lower than the lowest available
`
`strength.
`
`
`
`• Resume dose administered prior to inhibitor initiation, once the inhibitor is
`
`discontinued for 3 days.
`
`
`
`• Assess trough concentrations when initiating and discontinuing the inhibitor [see
`
` Dosage and Administration (2.8)].
`
`
`
`
`
`
`
` 2.12 Dosage Modifications for P-gp and CYP3A4 Inducers
`
` • Avoid concomitant use of St. John’s Wort (Hypericum perforatum).
`
`
`
`
` Increase the dose for patients taking AFINITOR/AFINITOR DISPERZ with a P-gp and strong CYP3A4 inducer as
`•
`
`
`
` recommended in Table 5 [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].
`
`
`
`
`
`
`
`
`Reference ID: 4780931
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Table 5: Recommended Dosage Modifications for Concurrent Use of AFINITOR/AFINITOR DISPERZ with P-gp
`
`
`
`
` and Strong CYP3A4 Inducers
`
` Indication
` Breast Cancer, NET, RCC, and
`
`
` TSC-Associated Renal
` Angiomyolipoma
`
`
` Dose Modification for AFINITOR/AFINITOR DISPERZ
` • Avoid coadministration where alternatives exist.
`
`
`
` • If coadministration cannot be avoided, double the daily dose using increments of 5 mg
`
`
`
`
`
`
`or less. Multiple increments may be required.
`
`
`
`
`• Resume the dose administered prior to inducer initiation, once an inducer is
`discontinued for 5 days.
`
`
`
`
`
`
`
`
`
`
`TSC-Associated SEGA and TSC-
`
` Associated Partial-Onset Seizures
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` • Double the daily dose using increments of 5 mg or less. Multiple increments may be
`
` required.
`
`
`• Addition of another strong CYP3A4 inducer in a patient already receiving treatment
`
`
`
`with a strong CYP3A4 inducer may not require additional dosage modification.
`
`
`
`• Assess trough concentrations when initiating and discontinuing the inducer [see
`
`
`Dosage and Administration (2.8)].
`
`• Resume the dose administered before starting any inducer, once all inducers are
`
`
` discontinued for 5 days.
`
`
` 2.13 Administration and Preparation
` • Administer AFINITOR/AFINITOR DISPERZ at the same time each day.
`
`
`
` • Administer AFINITOR/AFINITOR DISPERZ consistently either with or without food [see Clinical Pharmacology
`
`
` (12.3)].
`
`
`
`
`
` If a dose of AFINITOR/AFINITOR DISPERZ is missed, it can be administered up to 6 hours after the time it is
`
`
` normally administered. After more than 6 hours, the dose should be skipped for that day. The next day,
`
` AFINITOR/AFINITOR DISPERZ should be administered at its usual time. Double doses should not be administered
`
`
`
`
`
`
`
` to make up for the dose that was missed.
` AFINITOR
`
`• AFINITOR should be swallowed whole with a glass of water. Do not break or crush tablets.
`
`
`
`
`AFINITOR DISPERZ
`
`
`
`
`
`
`
`• Wear gloves to avoid possible contact with everolimus when preparing suspensions of AFINITOR DISPERZ for
`
`another person.
`
`
`
`• Administer as a suspension only.
`
`
`
`• Administer suspension immediately after preparation. Discard suspension if not administered within 60 minutes after
`
`preparation.
`
`• Prepare suspension in water only.
`
`
`
`
`Using an Oral Syringe to Prepare Oral Suspension:
`
`
`
`
`
`• Place the prescribed dose into a 10-mL syringe. Do not exceed a total of 10 mg per syringe. If higher doses are
`
`
`
`required, prepare an additional syringe. Do not break or crush tablets.
`
`
`
`
`
`
`• Draw approximately 5 mL of water and 4 mL of air into the syringe.
`
`
`
`
`
`
`
`
`• Place the filled syringe into a container (tip up) for 3 minutes, until the tablets are in suspension.
`
`
`
`
`• Gently invert the syringe 5 times immediately prior to administration.
`
`
`
`
`
`
`• After administration of the prepared suspension, draw approximately 5 mL of water and 4 mL of air into the same
`
`
`
`
`
`syringe, and swirl the contents to suspend remaining particles. Administer the entire contents of the syringe.
`
`
`
`•
`
`Reference ID: 4780931
`
`

`

`
`
` Using a Small Drinking Glass to Prepare Oral Suspension:
`
`
`
`
`
` • Place the prescribed dose into a small drinking glass (maximum size 100 mL) containing approximately 25 mL of
`
`
`
` water. Do not exceed a total of 10 mg per glass. If higher doses are required, prepare an additional glass. Do not break
`
`
` or crush tablets.
` • Allow 3 minutes for suspension to occur.
`
`
`
` • Stir the contents gently with a spoon, immediately prior to drinking.
`
` • After administration of the prepared suspension, add 25 mL of water and stir with the same spoon to re-suspend
`
`
` remaining particles. Administer the entire contents of the glass.
`
`
`
`
`
`
`
`
`
` DOSAGE FORMS AND STRENGTHS
` 3
`
`
` AFINITOR
`
`
`
`Tablets, white to slightly yellow and elongated with a bevelled edge:
`
`
`
`
`
`
`• 2.5 mg: engraved with “LCL” on one side and “NVR” on the other.
`
`
`
`
`• 5 mg: engraved with “5” on one side and “NVR” on the other.
`
`
`
`
`
`• 7.5 mg: engraved with “7P5” on one side and “NVR” on the other.
`
`
`
`
`
`• 10 mg: engraved with “UHE” on one side and “NVR” on the other.
`
`AFINITOR DISPERZ
`
`
`
`
`
`Tablets for oral suspension, white to slightly yellowish, round, and flat with a bevelled edge:
`
`
`
`
`• 2 mg: engraved with “D2” on one side and “NVR” on the other.
`
`
`
`
`• 3 mg: engraved with “D3” on one side and “NVR” on the other.
`
`
`
`
`• 5 mg: engraved with “D5” on one side and “NVR” on the other.
`
`
`
`CONTRAINDICATIONS
`4
`
`
`
`
`AFINITOR/AFINITOR DISPERZ is contraindicated in patients with clinically significant hypersensitivity to everolimus
`
`
`
`or to other rapamycin derivatives [see Warnings and Precautions (5.3)].
`
`
`
`
`WARNINGS AND PRECAUTIONS
`5
`
`
`Non-infectious Pneumonitis
`5.1
`
`
`
`Non-infectious pneumonitis is a class effect of rapamycin derivatives. Non-infectious pneumonitis was reported in up to
`
`
`
`
`
`19% of patients treated with AFINITOR/AFINITOR DISPERZ in clinical trials, some cases were reported with
`
`
`
`pulmonary hypertension (including pulmonary arterial hypertension) as a secondary event. The incidence of Grade 3 and
`
`
`4 non-infectious pneumonitis was up to 4% and up to 0.2%, respectively [see Adverse Reactions (6.1)]. Fatal outcomes
`
`have been observed.
`
`
`
`Consider a diagnosis of non-infectious pneumonitis in patients presenting with non-specific respiratory signs and
`
`
`
`
`symptoms. Consider opportunistic infections such as pneumocystis jiroveci pneumonia (PJP) in the differential diagnosis.
`
`
`Advise patients to report promptly any new or worsening respiratory symptoms.
`
`
`
`
`Continue AFINITOR/AFINITOR DISPERZ without dose alteration in patients who develop radiological changes
`
`
`
`
`suggestive of non-infectious pneumonitis and have few or no symptoms. Imaging appears to overestimate the incidence of
`
`clinical pneumonitis.
`
`
`
`
`
`For Grade 2 to 4 non-infectious pneumonitis, withhold or permanently discontinue AFINITOR/AFINITOR DISPERZ
`
`
`
`
`based on severity [see Dosage and Administration (2.9)]. Corticosteroids may be indicated until clinical symptoms
`
`
`resolve. Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are
`
`
`
`
`required. The development of pneumonitis has been reported even at a reduced dose.
`
`Reference ID: 4780931
`
`

`

` Infections
` 5.2
`
`
`
`
`
`
`
` AFINITOR/AFINITOR DISPERZ has immunosuppressive properties and may predispose patients to bacterial, fungal,
`
` viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1)]. Localized
` and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal
`
`
` infections (e.g., aspergillosis, candidiasis, or PJP), and viral infections (e.g., reactivation of hepatitis B virus) have
`
`
`
`
`
`
`
`
`
`
` occurred. Some of these infections have been severe (e.g., sepsis, septic shock, or resulting in multisystem organ failure)
`
`
`
`
` or fatal. The incidence of Grade 3 and 4 infections was up to 10% and up to 3%, respectively. The incidence of serious
`
`
`
` infections was reported at a higher frequency in patients < 6 years of age [see Use in Specific Populations (8.4)].
`
`
`
`
`
`
`
`
` Complete treatment of preexisting invasive fungal infections prior to starting treatment. Monitor for signs and symptoms
`
`
`
` of infection. Withhold or permanently discontinue AFINITOR/AFINITOR DISPERZ based on severity of infection [see
`
`
`
`
` Dosage and Administration (2.9)].
` Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required.
`
`
`
` Severe Hypersensitivity Reactions
`
`
`
` 5.3
`
`
` Hypersensitivity reactions to AFINITOR/AFINITOR DISPERZ have been observed and include anaphylaxis, dyspnea,
` flushing, chest pain, and angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment) [see
`
`
`
`
`
`
` Contraindications (4)]. The incidence of Grade 3 hypersensitivity reactions was up to 1%. Permanently discontinue
`
`
` AFINITOR/AFINITOR DISPERZ for the development of clinically significant hypersensitivity.
`
`
`
`
` Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors
`
`
`
` 5.4
`
`
` Patients taking concomitant ACE

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket